Compare Stocks

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVAX Evaxion Biotech A/S	$4.10	$3.57	$2.82 ▼ $18.50	$21.38M	-0.02	49,481 shs	44,814 shs
LGVN Longeveron	$2.93 +73.4%	$4.28	$1.62 ▼ $44.00	$4.25M	0.22	2.84 million shs	56.56 million shs
SBTX Silverback Therapeutics	$9.24 +2.4%	$8.53	$2.80 ▼ $8.97	$333.18M	0.6	337,931 shs	459,613 shs

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVAX Evaxion Biotech A/S	0.00%	+0.24%	+37.12%	-48.43%	-73.72%
LGVN Longeveron	+73.37%	+36.28%	-34.89%	-71.83%	-89.38%
SBTX Silverback Therapeutics	+2.44%	-6.95%	+0.87%	+56.35%	+54.52%

“Forget Tesla, this is Elon’s Next Big Thing” (Ad)

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EVAX Evaxion Biotech A/S	2.4806 of 5 stars	3.5	4.0	0.0	0.0	2.0	1.7	0.6
LGVN Longeveron	2.6508 of 5 stars	3.5	3.0	0.0	0.0	3.1	3.3	0.0
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVAX Evaxion Biotech A/S	3.00	Buy	$11.00	168.29% Upside
LGVN Longeveron	3.00	Buy	$60.00	1,947.78% Upside
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest LGVN, MDG1, EVAX, SBTX, and C4XD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2024	EVAX Evaxion Biotech A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
4/2/2024	EVAX Evaxion Biotech A/S	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$8.00
3/20/2024	EVAX Evaxion Biotech A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
2/12/2024	EVAX Evaxion Biotech A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00

(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVAX Evaxion Biotech A/S	$70K	305.74	N/A	N/A	($1.17) per share	-3.50
LGVN Longeveron	$710K	10.36	N/A	N/A	$2.68 per share	1.09
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVAX Evaxion Biotech A/S	-$22.12M	-$6.76	N/A	31.54	N/A	N/A	-451.63%	-149.27%	5/29/2024 (Estimated)
LGVN Longeveron	-$21.41M	-$10.20	N/A	N/A	N/A	-3,020.17%	-209.14%	-136.82%	5/10/2024 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	∞	N/A	N/A	-29.62%	-28.20%	N/A

Latest LGVN, MDG1, EVAX, SBTX, and C4XD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/27/2024	Q4 2023	EVAX Evaxion Biotech A/S	N/A	-$0.16	-$0.16	-$0.16	N/A	$0.07 million
2/27/2024	Q4 2023	LGVN Longeveron	-$2.10	-$2.50	-$0.40	-$0.25	$0.21 million	$0.06 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVAX Evaxion Biotech A/S	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVAX Evaxion Biotech A/S	N/A	1.18	1.18
LGVN Longeveron	0.21	1.50	1.50
SBTX Silverback Therapeutics	N/A	67.87	67.87

Ownership

Institutional Ownership

Company	Institutional Ownership
EVAX Evaxion Biotech A/S	11.04%
LGVN Longeveron	10.01%
SBTX Silverback Therapeutics	74.89%

Insider Ownership

Company	Insider Ownership
EVAX Evaxion Biotech A/S	41.64%
LGVN Longeveron	24.34%
SBTX Silverback Therapeutics	34.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
EVAX Evaxion Biotech A/S	63	5.22 million	3.04 million	Optionable
LGVN Longeveron	23	2.51 million	1.90 million	Not Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable

LGVN, MDG1, EVAX, SBTX, and C4XD Headlines

Source	Headline
	Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2% marketbeat.com - April 3 at 2:15 AM
	ARS Pharmaceuticals Inc (SPRY) uk.investing.com - May 11 at 1:32 PM
	Wild Isles wwf.org.uk - March 12 at 9:31 AM
	A look back at RNA Therapeutics – day one pharmaphorum.com - February 24 at 12:35 AM
	SPRY ARS Pharmaceuticals, Inc. seekingalpha.com - January 24 at 8:04 PM
	ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger 247wallst.com - November 22 at 6:29 AM
	Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics nasdaq.com - November 18 at 8:19 PM
	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis finance.yahoo.com - November 10 at 6:41 PM
	ARS Pharmaceuticals Closes Merger with Silverback Therapeutics finance.yahoo.com - November 8 at 5:59 PM
	Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions markets.businessinsider.com - October 28 at 8:15 AM
	FDA accepts ARS Pharma’s NDA for Neffy thepharmaletter.com - October 24 at 10:29 AM
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI kentuckytoday.com - October 23 at 7:22 PM
	Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis finance.yahoo.com - October 21 at 7:59 AM
	Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment? aaii.com - October 19 at 11:52 AM
	SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN bakersfield.com - October 12 at 11:07 PM
	INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT markets.businessinsider.com - September 17 at 5:10 AM
	SBTX Silverback Therapeutics, Inc. seekingalpha.com - September 15 at 10:58 PM
	SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT markets.businessinsider.com - September 6 at 11:53 AM
	SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY markets.businessinsider.com - August 23 at 6:32 PM
	SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTX apnews.com - August 17 at 12:02 PM
	SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTX apnews.com - August 11 at 1:33 AM
	SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations morningstar.com - July 30 at 7:00 AM
	INVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY apnews.com - July 28 at 2:21 AM
	Shareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTX benzinga.com - July 27 at 9:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Evaxion Biotech A/S

NASDAQ:EVAX

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Longeveron

NASDAQ:LGVN

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Silverback Therapeutics

NASDAQ:SBTX

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial